Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methyldopa in at-risk type 1 diabetes
NCT03396484Phase 2Withdrawn
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Sep 2020
- Primary completion
- Mar 2022
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of methyldopa in type 1 diabetes mellitus (T1D), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Planned start Sep 2020; status: withdrawn.
02
Drugs
methyldopa
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03396484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03396484.